Pasireotide

Pasireotide
Clinical data
Trade names Signifor
Synonyms SOM230
License data
Routes of
administration		 Subcutaneous
ATC code
Legal status
Legal status
  • In general: ℞ (Prescription only)
Identifiers
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ECHA InfoCard 100.211.883 Edit this at Wikidata
Chemical and physical data
Formula C58H66N10O9
Molar mass 1047.21 g/mol[1]
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

Pasireotide (SOM230, trade name Signifor[2]) is an orphan drug approved in the United States[3] and Europe[4] for the treatment of Cushing's disease in patients who fail or are ineligible for surgical therapy.[5][6] It was developed by Novartis. Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs.

Pasireotide was approved for Cushing's disease by the EMA in October 2009[7] and by the FDA in December 2012.[8]

Pasireotide LAR was approved by the FDA for treatment of acromegaly in December 2014, and had been approved for this indication by the EMA one month earlier.[9]

References

  1. ↑ Pasireotide | C58H66N10O9 - PubChem https://pubchem.ncbi.nlm.nih.gov/compound/Pasireotide
  2. ↑ Signifor® (pasireotide) Official Website for healthcare professionals outside the US http://www.signifor.com/
  3. ↑ http://www.accessdata.fda.gov/drugsatfda_docs/label/2012/200677lbl.pdf
  4. ↑ http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002052/WC500128056.pdf
  5. ↑ "Novartis drug Signifor® approved in the EU as the first medication to treat patients with Cushing's disease". Retrieved 2012-07-08.
  6. ↑ Mancini, Tatiana; Porcelli, Teresa; Giustina, Andrea (2010). "Treatment of Cushing disease: overview and recent findings". Therapeutics and Clinical Risk Management. 6: 505–16. doi:10.2147/TCRM.S12952. PMC 2963160. PMID 21063461.
  7. ↑ EMEA Approval for Pasireotide
  8. ↑ "FDA Approves Pasireotide for Cushing's Disease".
  9. ↑ Tucker, Miriam E. FDA Approves Pasireotide for Treating Acromegaly, Medscape, December 17, 2014, Retrieved 2015-08-21



This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.